RIGL Q4 2023 Earnings — Rigel Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RIGLRigel Pharmaceuticals, Inc.

$541M

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$36M-30.2% YoY

Gross Profit

$32M89.4% margin

Operating Income

$2M5.5% margin

Net Income

$737,0002.1% margin

EPS (Diluted)

$0.04

QoQ Revenue Growth

+27.2%

Cash Flow

Operating Cash Flow

-$6M

Free Cash Flow

-$6M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$117M

Total Liabilities

$146M

Stockholders' Equity

-$29M

Cash & Equivalents

$33M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$36M	$51M	-30.2%
Gross Profit	$32M	$51M	-37.2%
Operating Income	$2M	$2M	-5.4%
Net Income	$737,000	$1M	-47.4%

Revenue Segments

Gross product sales

$80M59%

Product sales, net

$57M41%